Bo Yang
Impact in
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 1%
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
Papers in
-
- Cancer, Hypoxia, and Metabolism 30
-
- Ubiquitin and proteasome pathways 40
- PI3K/AKT/mTOR signaling in cancer 26
- Retinoids in leukemia and cellular processes 22
- Cancer therapeutics and mechanisms 22
- Cell death mechanisms and regulation 20
Bo Yang
288 papers receiving 10.4k citations
Hit Papers
Peers
Comparison fields: 5 of 150
- Cancer Research 1.9k
- Molecular Biology 6.0k
- Oncology 2.1k
- Immunology 1.4k
- Toxicology 184
Countries citing papers authored by Bo Yang
This map shows the geographic impact of Bo Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Yang more than expected).
Fields of papers citing papers by Bo Yang
This network shows the impact of papers produced by Bo Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Yang. The network helps show where Bo Yang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bo Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 24 | |
| 7 | 2023 | 1 | |
| 8 | 2021 | 6 | |
| 9 | 2021 | 20 | |
| 10 | 2021 | 44 | |
| 11 | 2020 | 133 | |
| 12 | 2018 | 132 | |
| 13 | 2018 | 98 | |
| 14 | 2018 | 34 | |
| 15 | 2017 | 121 | |
| 16 | 2016 | 38 | |
| 17 | 2015 | 57 | |
| 18 | 2013 | 18 | |
| 19 | 2012 | 36 | |
| 20 | 2009 | 19 |
About Bo Yang
Bo Yang is a scholar working on Cancer Research, Molecular Biology, Oncology, Toxicology and Cell Biology, having authored 294 papers that have together received 10.5k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (40 papers), Cancer, Hypoxia, and Metabolism (30 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Autophagy in Disease and Therapy (23 papers), Cancer-related Molecular Pathways (22 papers), Retinoids in leukemia and cellular processes (22 papers), Cancer therapeutics and mechanisms (22 papers) and Cell death mechanisms and regulation (20 papers). The work is most often cited by research in Cancer Research (1.9k citations), Molecular Biology (6.0k citations), Oncology (2.1k citations), Immunology (1.4k citations) and Toxicology (184 citations). Bo Yang has collaborated with scholars based in China, United States and Czechia. Frequent co-authors include Qiaojun He, Ji Cao, Hong Zhu, Meidan Ying, Qinjie Weng, Yongzhou Hu, Peihua Luo, Ling Ding, Jincheng Wang and Jiajia Wang. Their work appears in journals such as European Journal of Medicinal Chemistry, Acta Pharmacologica Sinica, Biochemical Pharmacology, Acta Pharmaceutica Sinica B and European Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.